Empowered Funds LLC Sells 27,030 Shares of Humana Inc. $HUM

Empowered Funds LLC reduced its position in Humana Inc. (NYSE:HUM) by 26.3% in the first quarter, HoldingsChannel.com reports. The firm owned 75,592 shares of the insurance provider’s stock after selling 27,030 shares during the period. Empowered Funds LLC’s holdings in Humana were worth $13,107,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HUM. Revolve Wealth Partners LLC purchased a new stake in Humana in the 4th quarter worth $202,000. Woodline Partners LP lifted its position in shares of Humana by 460.0% in the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after acquiring an additional 8,372 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Humana by 53.7% in the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after acquiring an additional 452 shares during the period. Cresset Asset Management LLC boosted its stake in shares of Humana by 10.3% in the second quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock worth $581,000 after acquiring an additional 222 shares during the period. Finally, WINTON GROUP Ltd grew its position in shares of Humana by 58.5% during the second quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock worth $582,000 after purchasing an additional 879 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Piper Sandler reissued a “neutral” rating and set a $254.00 target price (up from $182.00) on shares of Humana in a research note on Wednesday, May 13th. Royal Bank Of Canada increased their price objective on shares of Humana from $246.00 to $415.00 and gave the company a “sector perform” rating in a report on Thursday, July 9th. TD Cowen lifted their price objective on shares of Humana from $211.00 to $350.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. Truist Financial boosted their target price on shares of Humana from $320.00 to $415.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Finally, Wells Fargo & Company upgraded shares of Humana from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $227.00 to $502.00 in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $335.87.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana reported second-quarter adjusted EPS of $7.61, above the $7.26 consensus estimate, while revenue reached approximately $40.9 billion, exceeding expectations and increasing 26.2% year over year. Medical costs were broadly in line with management’s expectations, with the Insurance segment benefit ratio at 91.2%. Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
• Positive Sentiment: The company affirmed its 2026 adjusted EPS guidance of at least $9.00 and maintained its expectation for approximately 25% growth in individual Medicare Advantage membership. CenterWell Senior Primary Care patient growth also remained strong, rising 27% year to date. Humana Reports Second Quarter 2026 Financial Results; Affirms Full Year 2026 Adjusted Financial Guidance
• Positive Sentiment: Bank of America upgraded Humana to “buy” and assigned a $500 price target, signaling confidence that the company’s recovery and margin-expansion initiatives can offset near-term pressure.
• Neutral Sentiment: Humana plans to exit additional Medicare Advantage plans for 2027 as it reshapes its portfolio around profitability. The move could improve margins but may limit membership growth and revenue in affected markets. Humana to exit more Medicare Advantage plans in 2027
• Negative Sentiment: Humana lowered its 2026 GAAP EPS outlook to at least $6.52 from at least $8.36, primarily reflecting the impact of lower Medicare Advantage Star Ratings. Although adjusted guidance was unchanged, investors may have expected an increase after the earnings beat. Humana Cuts Outlook Again on Lower Medicare Ratings
• Negative Sentiment: The company continues to forecast a year-over-year decline in 2026 adjusted earnings because of Medicare Advantage rating pressure, keeping concerns about the durability of its recovery in focus.

Humana Price Performance

NYSE:HUM opened at $365.89 on Thursday. The business’s 50-day moving average is $368.38 and its 200 day moving average is $267.06. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The company has a market capitalization of $43.93 billion, a P/E ratio of 39.13, a P/E/G ratio of 2.12 and a beta of 0.71. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, beating the consensus estimate of $7.26 by $0.35. Humana had a return on equity of 10.45% and a net margin of 0.82%.The business had revenue of $40.89 billion during the quarter, compared to analysts’ expectations of $40.57 billion. During the same quarter last year, the business posted $6.27 EPS. The firm’s revenue for the quarter was up 26.2% compared to the same quarter last year. On average, equities research analysts forecast that Humana Inc. will post 9.46 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.